Richard L. Doty

Prof. Richard L. Doty


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2012 in Nature Reviews Neurology
Verified
Journal Article
Closed access
RDRichard L. Doty
Richard L. Doty

17 April 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
PDF file
SMShima T. Moein
Shima T. Moein
SHSeyed MohammadReza Hashemian
Seyed MohammadReza Hashemian
BMBabak Mansourafshar
Babak Mansourafshar
AKAli Khorram‐Tousi
Ali Khorram‐Tousi
PTPayam Tabarsi
Payam Tabarsi
RDRichard L. Doty
Richard L. Doty
Background: Severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2), the virus that causes coronavirus disease 2019 (COVID‐19), is responsible for the largest pandemic since the 1918 influenza A virus subtype H1N1 influenza outbreak. The symptoms presently recognized by the World Health Organization are cough, fever, tiredness, and difficulty breathing. Patient‐reported smell and taste loss has been associated with COVID‐19 infection, yet no empirical olfactory testing on a cohort of COVID‐19 patients has been performed.Methods: The University of Pennsylvania Smell Identification Test (UPSIT), a well‐validated 40‐odorant test, was administered to 60 confirmed COVID‐19 inpatients and 60 age‐ and sex‐matched controls to assess the magnitude and frequency of their olfactory dysfunction. A mixed effects analysis of variance determined whether meaningful differences in test scores existed between the 2 groups and if the test scores were differentially influenced by sex.Results: Fifty‐nine (98%) of the 60 patients exhibited some smell dysfunction (mean [95% CI] UPSIT score: 20.98 [19.47, 22.48]; controls: 34.10 [33.31, 34.88]; p < 0.0001). Thirty‐five of the 60 patients (58%) were either anosmic (15/60; 25%) or severely microsmic (20/60; 33%); 16 exhibited moderate microsmia (16/60; 27%), 8 mild microsmia (8/60; 13%), and 1 normosmia (1/60; 2%). Deficits were evident for all 40 UPSIT odorants. No meaningful relationships between the test scores and sex, disease severity, or comorbidities were found.Conclusion: Quantitative smell testing demonstrates that decreased smell function, but not always anosmia, is a major marker for SARS‐CoV‐2 infection and suggests the possibility that smell testing may help, in some cases, to identify COVID‐19 patients in need of early treatment or quarantine.

1 January 2014 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
RDRichard L. Doty
Richard L. Doty
VKVidyulata Kamath
Vidyulata Kamath
Decreased olfactory function is very common in the older population, being present in over half of those between the ages of 65 and 80 years and in over three quarters of those over the age of 80 years. Such dysfunction significantly influences physical well-being and quality of life, nutrition, the enjoyment of food, as well as everyday safety. Indeed a disproportionate number of the elderly die in accident gas poisonings each year. As described in this review, multiple factors contribute to such age-related loss, including altered nasal engorgement, increased propensity for nasal disease, cumulative damage to the olfactory epithelium from viral and other environmental insults, decrements in mucosal metabolizing enzymes, ossification of cribriform plate foramina, loss of selectivity of receptor cells to odorants, changes in neurotransmitter and neuromodulator systems, and neuronal expression of aberrant proteins associated with neurodegenerative disease. It is now well established that decreased smell loss can be an early sign of such neurodegenerative diseases as Alzheimer’s disease and idiopathic Parkinson’s disease. In this review we provide an overview of the anatomy and physiology of the aging olfactory system, how this system is clinically evaluated, and the multiple pathophysiological factors that are associated with its dysfunction.

1 May 2009 in Physiology & Behavior
Verified
Journal Article
Closed access
RDRichard L. Doty
Richard L. Doty
ECE. Leslie Cameron
E. Leslie Cameron

1 June 2012 in Neurobiology of Disease
Verified
Journal Article
Closed access
RDRichard L. Doty
Richard L. Doty